Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

BMS Partners with Tigerlily Foundation to Address Racial Disparities in Breast Cancer Clinical Trial Access – Pharma Giant Commits to Improving Representation of Young Women of Color

Fineline Cube May 18, 2026
Company Deals

Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals – Strategic Retreat from Allogeneic Cell Therapy Market in Asia

Fineline Cube May 18, 2026
Company Deals

Eli Lilly Commits $50M to UNICEF USA Alliance Targeting Non-Communicable Disease Prevention in Children Across 21 LMICs

Fineline Cube May 15, 2026
Company Deals

TenNor Therapeutics Raises $71M in Hong Kong IPO – Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections

Fineline Cube May 14, 2026
Company Deals Drug

Fosun Pharma Secures Global Rights to AriBio’s Alzheimer’s Drug AR1001 in $240M Deal – PDE-5 Inhibitor Shows Promise in Phase III

Fineline Cube May 14, 2026
Policy / Regulatory

China Issues National Guidelines for Home Hospital Bed Services to Address Healthcare Access for Vulnerable Populations

Fineline Cube May 15, 2026
Company Drug

Regeneron’s Fianlimab-Cemiplimab Combination Fails to Meet Primary Endpoint in Phase III Melanoma Trial – LAG-3/PD-1 Dual Therapy Shows No PFS Benefit Over Pembrolizumab Monotherapy

Fineline Cube May 18, 2026
Company Drug

AstraZeneca’s Baxfendy Secures FDA Approval for Uncontrolled Hypertension – First-in-Class Aldosterone Synthase Inhibitor with Selective CYP11B2 Targeting

Fineline Cube May 18, 2026
Company Deals

BeiGene and InnoRNA Partner on mRNA-LNP Therapeutic Development

Fineline Cube Jul 7, 2022

China-based biotech firm BeiGene (HKG: 6160, SHA: 688235, NASDAQ: BGNE) announced a strategic partnership with...

Company Deals

PackGene and SineuGene Partner on ALS Gene Therapy Research

Fineline Cube Jul 7, 2022

China-based PackGene has entered into another partnership with compatriot firm SineuGene. This time, the focus...

Policy / Regulatory

China Establishes Leadership Group to Combat Drug-Related Crimes

Fineline Cube Jul 7, 2022

China’s State Council executive body released a notification regarding the establishment of a leadership group...

Company Deals Digital

Phil Rivers Tech Raises RMB 100 Million for Computational Medicine Push

Fineline Cube Jul 7, 2022

Beijing-based Phil Rivers Tech, a computational medicine-empowered drug developer, reportedly raised close to RMB 100...

Company Drug

Gan & Lee Pharmaceuticals Doses First Patient in GZR101 Phase I Study

Fineline Cube Jul 7, 2022

China-based Gan & Lee Pharmaceuticals (SHA: 603087) announced that the first patient has been dosed...

Company Drug

Fosun Pharma’s FS-1502 Gets NMPA Approval for Gastric Cancer Study

Fineline Cube Jul 6, 2022

China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that it has...

Company Drug

GeneScience’s Somatropin Wins NMPA Approval for Prader-Willi Syndrome

Fineline Cube Jul 6, 2022

China-based Changchun GeneScience Pharmaceutical Co., Ltd announced that it has received another indication approval from...

Company Drug

Inmagene and HutchMed Dose First Patient in IMG-007 Global Phase I Study

Fineline Cube Jul 6, 2022

China-based Inmagene Biopharmaceuticals and HutchMed (NASDAQ: HCM, HKG: 0013) announced the completion of first patient...

Company Deals

ClinChoice Raises USD 150M in Funding Led by Legend Capital for Expansion

Fineline Cube Jul 6, 2022

Sino-US full-service Contract Research Organization (CRO) ClinChoice has reportedly raised USD 150 million in a...

Drug

InnoCare Pharma’s BCL2 Inhibitor ICP-248 Accepted for NMPA Review

Fineline Cube Jul 6, 2022

China’s Beijing InnoCare Pharma (HKG: 9969) announced that an investigational new drug (IND) filing for...

Company Deals

Shenzhen TargetRx Raises Hundreds of Millions in Series B Financing for Drug Development

Fineline Cube Jul 6, 2022

China-based Shenzhen TargetRx, Inc., a developer of small-molecule kinase inhibitors, reportedly raised “hundreds of millions”...

Drug

Ascletis Pharma Files IND Application for ASC10 with US FDA

Fineline Cube Jul 6, 2022

China-based Ascletis Pharma Inc. (HKG: 1672) announced that it has filed an Investigational New Drug...

Company Drug

MabPharm’s CMAB017 Receives NMPA Approval for Clinical Study in Solid Tumors

Fineline Cube Jul 6, 2022

Taizhou-based monoclonal antibody (mAb) biosimilars specialist MabPharm Ltd (HKG: 2181) announced that it has received...

Company Deals

Zhejiang Medicine’s NovoCodex Subsidiary Receives RMB 402M Investment

Fineline Cube Jul 6, 2022

China-based Zhejiang Medicine Co., Ltd (SHA: 600216) announced that investors will inject a financial dose...

Company Deals

Medicilon Biomedical Plans RMB 2.16B Private Placement for R&D Expansion

Fineline Cube Jul 6, 2022

China-based Shanghai Medicilon Biomedical Co., Ltd has announced plans to raise RMB 2.16 billion (USD...

Company Drug

Hansoh Pharmaceutical’s Generic Ibrance Approved by NMPA

Fineline Cube Jul 6, 2022

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced that it has received market approval...

Company Digital

Alibaba Health’s 2022 Financial Report Shows Revenue Growth, Net Loss

Fineline Cube Jul 6, 2022

China-based Alibaba Health Information Technology Ltd (HKG: 0241) released its 2022 financial report (for the...

Company Policy / Regulatory

Wuxi Biologics Set to Be Removed from US Restricted Trade List

Fineline Cube Jul 6, 2022

Wuxi Biologics (HKG: 2269) is reportedly on the verge of being removed from a US...

Policy / Regulatory R&D

CDE Releases 60th Batch of Chemical Generic Reference Preparations

Fineline Cube Jul 6, 2022

The Center for Drug Evaluation (CDE) has released the 60th batch of chemical generic reference...

Company Deals

Beijing Tianshi Tongda Raises RMB 140M for Autoimmune Disease Therapies

Fineline Cube Jul 5, 2022

China-based Beijing Tianshi Tongda Pharmaceuticals Technology Co., Ltd has reportedly raised RMB 140 million (USD...

Posts pagination

1 … 654 655 656 … 667

Recent updates

  • BMS Partners with Tigerlily Foundation to Address Racial Disparities in Breast Cancer Clinical Trial Access – Pharma Giant Commits to Improving Representation of Young Women of Color
  • Regeneron’s Fianlimab-Cemiplimab Combination Fails to Meet Primary Endpoint in Phase III Melanoma Trial – LAG-3/PD-1 Dual Therapy Shows No PFS Benefit Over Pembrolizumab Monotherapy
  • AstraZeneca’s Baxfendy Secures FDA Approval for Uncontrolled Hypertension – First-in-Class Aldosterone Synthase Inhibitor with Selective CYP11B2 Targeting
  • Harbour BioMed Unveils Preclinical Data for LET003 – AI-Discovered ACVR2A/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs
  • Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals – Strategic Retreat from Allogeneic Cell Therapy Market in Asia
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

BMS Partners with Tigerlily Foundation to Address Racial Disparities in Breast Cancer Clinical Trial Access – Pharma Giant Commits to Improving Representation of Young Women of Color

Company Drug

Regeneron’s Fianlimab-Cemiplimab Combination Fails to Meet Primary Endpoint in Phase III Melanoma Trial – LAG-3/PD-1 Dual Therapy Shows No PFS Benefit Over Pembrolizumab Monotherapy

Company Drug

AstraZeneca’s Baxfendy Secures FDA Approval for Uncontrolled Hypertension – First-in-Class Aldosterone Synthase Inhibitor with Selective CYP11B2 Targeting

Company Drug

Harbour BioMed Unveils Preclinical Data for LET003 – AI-Discovered ACVR2A/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.